| Literature DB >> 31034511 |
Hye Yin Park1,2, Yun-Chul Hong2,3,4, Kyoungho Lee1, Jaewoo Koh1.
Abstract
PURPOSE: This meta-analysis aimed to extensively investigate the association between various measures of vitamin D status and non-Hodgkin lymphoma (NHL) and its subtypes.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31034511 PMCID: PMC6488072 DOI: 10.1371/journal.pone.0216284
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram of identification of relevant studies.
General characteristics of the studies on vitamin D status and non-Hodgkin lymphoma risk.
| Author | Ref. no. | Type | Study | Country | Recruit period | Case no. | Control/ pop. no. | Exposure | Outcome | Matched/adjusted variables |
|---|---|---|---|---|---|---|---|---|---|---|
| Erber et al., 2010 | [ | cohort | MEC (multiethnic cohort)1) | USA | 1993–1996 | male 514, female 425 | 193,050 | diet | NHL, DLBL, FL, CLL/SLL | education, body mass index, alcohol intake, total energy intake (plus race/ethnicity) |
| Freedman et al., 2010 | [ | cohort | USRT study | USA | 1983–2005 | 137 | 64,103 | sunlight/UVR (v, vii) | NHL | age, sex, race/ethnicity |
| Veierød et al., 2010 | [ | cohort | Norwegian-Swedish Women's Lifestyle and Health Cohort Study | Sweden, Norway | 1991–1992 | 158 | 104,953 | sunlight/UVR (i, ii, iii) | NHL | age, region of residence, eye color, hair color, skin reaction after heavy sun exposure in the beginning of the summer and after repeated sun exposure (plus solar exposure in artificial tanning) |
| Bertrand et al., 2011 | [ | cohort | NHS (Nurses' Health Study)1) | USA | 1976–2006 | 808 | 115,482 | sunlight/UVR (v); diet | NHL, DLBL, FL, CLL/SLL (dietary: only NHL) | age, smoking, body mass index, height |
| Chang et al., 2011 | [ | cohort | CTS (California Teachers Study) | USA | 1995–1996 | 629 | 121,216 | sunlight/UVR (v); diet | NHL, DLBL, FL, CLL/SLL (dietary: only NHL) | age, calendar-year effect |
| Lin et al., 2012 | [ | cohort | NIH-AARP Diet and Health Study | USA | 1995–1996 | NHL 2,731, DLBL 1,059, FL 577, CLL/SLL 237, T-cell 188 | 450,934 | sunlight/UVR (v) | NHL, DLBL, FL, CLL/SLL, T-cell | age at baseline, sex, BMI, caloric intake, intake of fruit, vegetables, red and white meat, alcohol consumption, tobacco smoking, education, physical activity, median household income |
| Zhang et al., 2013 | [ | cohort | NHS II | USA | 1989–2009 | 185 | 73,358 | sunlight/UVR (iii) | NHL | age,body mass index, alcohol, physical activity, multivitamin, smoking, oral contraceptive use, menopausal status, hormone replacement therapy use, outdoor sun exposure during high school/college, at 25-35years, UV index of residence, dietary & supplementary vitamin D intake |
| Hughes et al., 2004 | [ | case-control | (NSW) | Australia | 2000–2001 | 704 | 694 | sunlight/UVR (ii) | NHL | age, sex, state of residence at diagnosis, ethnicity, skin color, ability to tan |
| Smedby et al., 2005 | [ | case-control | SCALE (Scandinavian lymphoma etiology) | Denmark, Sweden | 1999–2002 | 3,055 | 3,187 | sunlight/UVR (i, ii, iii, iv) | NHL, DLBL, FL, CLL, T-cell | age, sex, country, skin type |
| Chang et al., 2006 | [ | case-control | SCALE (Scandinavian lymphoma etiology) | Sweden | 2000–2002 | 591 | 460 | diet | NHL, DLBL, FL, CLL, T-cell | age, sex, total energy intake, intake of retinol/vitamin D/calcium/phosphorus |
| Hartge et al., 2006 | [ | case-control | (SEER) | USA | 1998–2002 | 551 | 462 | sunlight/UVR (i, iii, iv, v); diet | NHL | age, sex, race/ethnicity, study region, exercise, total energy intake |
| Polesel et al., 2006 | [ | case-control | (Aviano-Naples) | Italy | 1999–2002 | 190 | 484 | diet | NHL, DLBL, FL | age, sex, center, education, place of birth, HCV test, total energy intake |
| Soni et al., 2007 | [ | case-control | (Nebraska) | USA | 1999–2002 | 387 | 535 | sunlight/UVR (v); diet | NHL, DLBL, FL, CLL/SLL, MZL, B-/T-cell | age, sex, family history of cancer |
| Weihkopf et al., 2007 | [ | case-control | Germany | 1999–2003 | 589 | 589 | sunlight/UVR (ii, iv, vi) | DLBL, FL, CLL/SLL, MZL, B-/T-cell | age, sex, region, smoking status, alcohol consumption | |
| Zhang et al., 2007 | [ | case-control | (Yale) | USA | 1996–2000 | 601 | 717 | sunlight/UVR (i, ii, iv) | NHL, DLBL, FL, CLL/SLL, MZL, B-/T-cell | age, race/ethnicity, family history of NHL, education, eye color, skin type |
| Boffetta et al., 2008 | [ | case-control | Epilymph | France, Germany, Ireland, Italy, Spain | 1998–2004 | 1,518 | 2,124 | sunlight/UVR (iii, v) | NHL, DLBL, FL, CLL/SLL, B-cell, T-cell | age, sex, region(center), education, skin reaction to sun, questionnaire type |
| Grandin et al., 2008 | [ | case-control | Engela (France) | France | 2000–2004 | 395 | 698 | sunlight/UVR (iii, vi) | NHL | age, sex, region(center), outdoor activity frequency, artificial radiation/outdoor activity (stratified) |
| Kricker et al., 2008 | [ | case-control | InterLymph (older) | N.America, Europe, Australia | 1995–2005 | 8,243 | 9,697 | sunlight/UVR (vii, viii) | NHL, DLBL, FL, CLL/SLL, MZL, B-/T-cell | age, sex, race/ethnicity, study |
| Kelly et al., 2010 | [ | case-control | (Univ. of Rochester) | USA | 2005–2007 | 129 | 139 | sunlight/UVR (i, iii, iv, vii); 25(OH)D | NHL | sunlight/UVR: age, sex, race/ethnicity, skin cancer diagnosis, family history of lymphoma & other cancer, body mass index, alcohol, sun exposure variables (eg. sunburn, tanning) |
| Purdue et al., 2010 | [ | case-control | VDPP (Vitamin D Pooling Project of Rarer Caners; ATBC, CPS-II, MEC, NHS, NYU-WHS, PLCO, SMHS, SWHS | USA, Finland, China | 1974–2008 | 1,353 | 1,778 | 25(OH)D | NHL, DLBL, FL, CLL/SLL | age at blood collection, sex, race/ethnicity, date of blood draw, height (plus menopausal status) |
| Kelly et al., 2012 | [ | case-control | (Mayo Clinic) | USA | 2002–2008 | 1,009 | 1,233 | sunlight/UVR (vii) | NHL, DLBL, FL, CLL/SLL | age, sex, region, family history of lymphoma |
| Mikhak et al., 2012 | [ | case-control | (UCSF-II) | USA | 2001–2006 | 2,052 | 2,081 | diet | NHL, DLBL, FL, CLL/SLL, MZL, T-cell | age, sex, county, total energy intake |
| Wong et al., 2012 | [ | case-control | Singapore | 2004–2008 | 465 | 830 | sunlight/UVR (vi) | NHL, B-/T-cell | age, sex, region(center), month of diagnosis, ethnicity, skin color, education, housing type, body mass index, history of any cancer in 1st-degree relatives | |
| Łuczyńska et al., 2013 | [ | case-control | EPIC (European Prospective Investigation into Cancer and Nutrition) | Denmark, Italy, Netherlands, Norway, Spain, Sweden, UK, Germany, Greece | 1992–2000 | 1,127 | 1,127 | diet; 25(OH)D | DLBL, FL, CLL, B-cell | age, sex, region(center), follow-up length, time and date of blood collection, smoking status, alcohol consumption at baseline, education, BMI, physical education, total energy and calcium intake |
| Cerhan et al., 2014 | [ | case-control | InterLymph | N.America, Europe, Australia | 1976–2008 | 4,667 | 22,639 | sunlight/UVR (viii) | DLBL | age, sex, race/ethnicity, study |
| Linet et al., 2014 | [ | case-control | InterLymph | N.America, Europe, Australia | 1976–2008 | 3,530 | 22,639 | sunlight/UVR (vii, viii) | FL | age, sex, race/ethnicity, study |
| Slager et al., 2014 | [ | case-control | InterLymph | N.America, Europe, Australia | 1976–2008 | 2,440 | 15,186 | sunlight/UVR (vii, viii) | CLL/SLL | age, sex, race/ethnicity, study |
| Bracci PM et al., 2014 | [ | case-control | InterLymph | N.America, Europe, Australia | 1976–2008 | 13,766 | 1,052 | sunlight/UVR (viii) | MZL | age, sex, race/ethnicity, study |
| Kleinstern et al., 2017 | [ | case-control | Israel, Palestine | 2010–2014 | 823 | 808 | sunlight/UVR (vi) | DLBL, FL, B-cell | age, sex, marital status, education, ethnic origin, residential region | |
| Wang et al., 2017 | [ | case-control | LA County NHL Case-Control Study | USA | 2004–2008 | 625 | 625 | sunlight/UVR (i, iii) | DLBL, FL, CLL/SLL, MZL, B-cell | age, race/ethnicity, socioeconomic status, standard error of skewness, family history of cancer |
Abbreviations: NHL, non-Hodgkin lymphoma; DLBL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia and small lymphocytic lymphoma, MZL, marginal zone lymphoma.
1) Later integrated to VDPP study; exposure-outcome measures do not overlap in the current study
2, 3) Later integrated to InterLymph study; exposure-outcome measures do not overlap (2) or partly overlap (3) in the current study
*underlined exposure measures were selected in the main analysis as the overall sunlight/UVR exposure indices: (i) sunburn; (ii) bathing vacation; (iii) artificial tanning; (iv) sunbath/suntan; (v) ambient exposure; (vi) outdoor/recreational activity; (vii) total exposure; (viii) recreational exposure
Risk estimates on vitamin D status and non-Hodgkin lymphoma risk by different sources of exposure.
| Summary RR (95% CI) | Study no. | I2 | p-hetero | Begg's test | Egger's test | ||
|---|---|---|---|---|---|---|---|
| NHL | All | 0.80 (0.71–0.90) | 17 | 65.8% | 0.000. | 0.387 | 0.259 |
| Cohort study | 0.88 (0.72–1.06) | 6 | 76.6% | 0.001 | 0.707 | 0.793 | |
| Case-control study | 0.75 (0.68–0.82) | 11 | 38.9% | 0.090 | 1.000 | 0.835 | |
| NOS ≥7 | 0.80 (0.75–0.86) | 10 | 49.2% | 0.039 | 0.283 | 0.407 | |
| General population | 0.77 (0.72–0.82) | 14 | 42.1% | 0.048 | 1.000 | 0.450 | |
| DLBL | All | 0.72 (0.54–0.97) | 7 | 80.7% | 0.000. | 0.23 | 0.313 |
| Exc. Kleinstern [ | 0.67 (0.53–0.84) | 6 | 58.4% | 0.035 | 0.06 | 0.031 | |
| FL | All | 0.81 (0.73–0.90) | 8 | 48.3% | 0.060 | 0.711 | 0.574 |
| Exc. Kleinstern [ | 0.78 (0.70–0.88) | 7 | 26.7% | 0.225 | 1.000 | 0.982 | |
| CLL/SLL | All | 0.87 (0.68–1.11) | 6 | 54.6% | 0.051 | 0.707 | 0.796 |
| MZL | All | 0.70 (0.57–0.87) | 3 | 5.5% | 0.347 | n/a | n/a |
| B-cell | All | 0.84 (0.68–1.05) | 8 | 73.4% | 0.000. | 0.902 | 0.724 |
| Exc. Kleinstern [ | 0.76 (0.68–0.85) | 7 | 43.5% | 0.101 | 1.000 | 0.661 | |
| T-cell | All | 0.70 (0.48–1.01) | 8 | 64.2% | 0.007 | 1.000 | 0.607 |
| NHL | All | 1.03 (0.90–1.19) | 9 | 56.9% | 0.018 | 0.466 | 0.084 |
| Cohort study | 1.03 (0.90–1.17) | 4 | 0.0% | 0.583 | n/a | n/a | |
| Case-control study | 0.995 (0.76–1.30) | 5 | 73.8% | 0.004 | n/a | n/a | |
| DLBL | Ref. by 200IU/d | 0.98 (0.81–1.20) | 7 | 0.0% | 0.550 | n/a | n/a |
| Ref. by max. intake | 0.98 (0.80–1.21) | 7 | 0.0% | 0.547 | n/a | n/a | |
| FL | Ref. by 200IU/d | 1.04 (0.81–1.33) | 7 | 45.9% | 0.085 | n/a | n/a |
| Ref. by max. intake | 0.96 (0.74–1.24) | 7 | 26.1% | 0.229 | n/a | n/a | |
| CLL/SLL | Ref. by 200IU/d | 0.95 (0.61–1.48) | 6 | 57.3% | 0.039 | n/a | n/a |
| Ref. by max. intake | 0.99 (0.73–1.33) | 6 | 41.4% | 0.130 | n/a | n/a | |
| MZL | Ref. by 200IU/d | 0.98 (0.54–1.77) | 2 | 0.0% | 0.612 | n/a | n/a |
| Ref. by max. intake | 0.91 (0.49–1.70) | 2 | 0.0% | 0.730 | n/a | n/a | |
| T-cell | Ref. by 200IU/d | 1.49 (0.84–2.66) | 3 | 0.0% | 0.642 | n/a | n/a |
| Ref. by max. intake | 1.55 (0.83–2.88) | 3 | 45.2% | 0.161 | n/a | n/a | |
| NHL | All | 0.97 (0.82–1.15) | 3 | 0.0% | 0.543 | n/a | n/a |
| Exc. Łuczyńska [ | 1.01 (0.82–1.24) | 2 | 0.0% | 0.374 | n/a | n/a | |
| DLBL | All | 1.01 (0.74–1.37) | 2 | 0.0% | 0.437 | n/a | n/a |
| FL | All | 1.20 (0.83–1.72) | 2 | 0.0% | 0.453 | n/a | n/a |
| CLL/SLL | All | 0.82 (0.62–1.10) | 2 | 6.3% | 0.302 | n/a | n/a |
Meta-analyses results are presented in summary relative risks (RR) and their 95% confidence intervals (95% CI). Kleinstern et al. [42] is a study with influence on heterogeneity; Łuczyńska et al., [17] is a study with outcome in B-cell NHL (not NHL) but was included in line with a previous meta-analysis.
Fig 2Meta-analysis of the association between vitamin D status and non-Hodgkin lymphoma incidence by different sources of exposure.
(a) overall sunlight/UVR exposure; (b) dietary vitamin D intake; (c) serum/plasma 25-hydroxyvitamin D. Meta-analyses results are presented in summary relative risks (RR) and their 95% confidence intervals (95% CI).
Sunlight/UVR exposure in various measures and non-Hodgkin lymphoma risk.
| NHL | DLBL | FL | CLL/SLL | MZL | B-cell | T-cell | ||
|---|---|---|---|---|---|---|---|---|
| Summary RR (95% CI) | 0.80 (0.71–0.90) | 0.73 (0.62–0.86) | 0.77 (0.71–0.84) | 0.87 (0.80–0.94) | 0.70 (0.57–0.87) | 0.76 (0.68–0.85) | 0.70 (0.48–1.01) | |
| Study no. (I2) | 17 (65.8%) | 7 (57.4%) | 8 (16.0%) | 7 (45.5%) | 3 (5.5%) | 7 (43.5%) | 8 (64.2%) | |
| p-heterogeneity | < .001 | 0.029 | 0.305 | 0.088 | 0.347 | 0.101 | 0.007 | |
| Summary RR (95% CI) | 0.72 (0.62–0.83) | 0.57 (0.46–0.71) | 0.74 (0.58–0.95) | 0.65 (0.49–0.87) | 0.91 (0.52–1.58) | 0.76 (0.61–0.94) | 0.72 (0.41–1.25) | |
| Study no. (I2) | 5 (26.9%) | 3 (48.8%) | 3 (0.0%) | 3 (0.0%) | 2 (0.0%) | 2 (0.0%) | 2 (33.4%) | |
| p-heterogeneity | 0.243 | 0.142 | 0.889 | 0.707 | 0.418 | 0.418 | 0.221 | |
| Summary RR (95% CI) | 0.91 (0.59–1.40) | 0.78 (0.61–0.99) | 0.74 (0.45–1.20) | 0.65 (0.52–0.81) | 1.08 (0.30–3.93) | 0.98 (0.38–2.57) | 0.75 (0.54–1.05) | |
| Study no. (I2) | 4 (88.0%) | 3 (32.6%) | 3 (50.4%) | 3 (85.7%) | 2 (54.0%) | 2 (91.9%) | 3 (0.0%) | |
| p-heterogeneity | < .001 | 0.227 | 0.133 | 0.001 | 0.140 | < .001 | 0.603 | |
| Summary RR (95% CI) | 0.92 (0.84–1.003) | 0.83 (0.66–1.06) | 0.92 (0.49–1.74) | 1.001 (0.80–1.26) | - | 0.95 (0.57–1.59) | 1.23 (0.86–1.75) | |
| Study no. (I2) | 7 (30.2%) | 2 (0.0%) | 2 (74.4%) | 2 (0.0%) | - | 2 (74.1%) | 2 (0.0%) | |
| p-heterogeneity | 0.198 | 0.39 | 0.048 | 0.98 | - | 0.049 | 0.822 | |
| Summary RR (95% CI) | 0.78 (0.50–1.23) | 0.64 (0.36–1.15) | 0.60 (0.45–0.81) | 0.63 (0.51–0.79) | 1.24 (0.11–14.03) | 0.94 (0.38–2.30) | 0.89 (0.55–1.43) | |
| Study no. (I2) | 4 (77.6%) | 3 (70.1%) | 3 (0.0%) | 3 (34.0%) | 2 (72.8%) | 2 (86.8%) | 3 (0.0%) | |
| p-heterogeneity | 0.004 | 0.035 | 0.398 | 0.22 | 0.055 | 0.006 | 0.987 | |
| Summary RR (95% CI) | 0.79 (0.67–0.92) | 0.72 (0.51–1.01) | 0.85 (0.72–1.02) | 0.96 (0.76–1.19) | - | 0.77 (0.64–0.94) | 0.55 (0.40–0.75) | |
| Study no. (I2) | 7 (66.8%) | 3 (51.7%) | 4 (0.0%) | 4 (0.0%) | - | 2 (0.0%) | 3 (38.9%) | |
| p-heterogeneity | 0.006 | 0.126 | 0.410 | 0.480 | - | 0.810 | 0.195 | |
| Summary RR (95% CI) | 0.77 (0.59–0.99) | 1.30 (0.98–1.74) | 1.24 (0.83–1.85) | - | - | 1.09 (0.91–1.31) | 0.25 (0.10–0.60) | |
| Study no. (I2) | 2 (0.0%) | 2 (0.0%) | 2 (0.0%) | - | - | 3 (49.5%) | 2 (0.0%) | |
| p-heterogeneity | 0.354 | 0.708 | 0.869 | - | - | 0.138 | 0.437 | |
| Summary RR (95% CI) | 0.82 (0.69–0.97) | - | - | - | - | - | - | |
| Study no. (I2) | 4 (0.0%) | - | - | - | - | - | - | |
| p-heterogeneity | 0.572 | - | - | - | - | - | - |